ProfileGDS5678 / 1434236_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 90% 89% 88% 87% 88% 86% 83% 86% 90% 91% 89% 88% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9274689
GSM967853U87-EV human glioblastoma xenograft - Control 27.2660390
GSM967854U87-EV human glioblastoma xenograft - Control 37.1424189
GSM967855U87-EV human glioblastoma xenograft - Control 47.0404588
GSM967856U87-EV human glioblastoma xenograft - Control 56.7491387
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.666288
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4103986
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0751583
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.5680986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2291790
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.3281691
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1772589
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8839388
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.2976391